EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY 4.0

Predictive factors for eczematous eruptions and candidiasis during anti-interleukin-17 treatment in patients with psoriasis: a multicentre real-life experience in Lazio region, Italy

Giacomo Caldarola iD, Eleonora De Luca, Simone Amato iD, Alfredo Belcastro, Nicoletta Bernardini iD, Luca Bianchi, Annunziata Dattola, Clara De Simone, Gaia Moretta, Sabatino Pallotta, Ketty Peris, Antonio Richetta und 3 weitere

Clinical and Experimental Dermatology · 2025

DOI: 10.1093/ced/llaf271 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Clinical and Experimental Dermatology, 2025. Verfasst von Giacomo Caldarola und 14 weiteren Autor:innen. Beteiligte Einrichtung: UOC di Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli - IRCCS, Rome,Italy. Hauptthemen laut MEDLINE: Psoriasis, Interleukin-17, Eczema, Dermatologic Agents. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Anti-interleukin (IL)-17 treatments have revolutionized psoriasis treatment, offering excellent clinical outcomes and safety profiles. However, these drugs have been associated with class-specific side effects, including Candida infections and eczematous reactions.

Objectives

To assess the frequency of Candida infections and cutaneous eczematous eruptions in patients with plaque psoriasis treated with secukinumab, ixekizumab, brodalumab or bimekizumab and to identify risk factors.

Methods

A multicentre, retrospective, observational study was conducted involving patients with plaque psoriasis treated with anti-IL-17 biologics at five outpatient clinics in Lazio, Italy. Demographic data, clinical data, treatment characteristics and adverse events were analysed. Cox regression models were used to identify factors associated with the occurrence of these adverse events.

Results

Of 1075 patients, 34 (3.2%) developed eczema, and 36 (3.3%) had candidiasis. Treatment was discontinued in 78% of patients who developed eczema and 50% of patients who had candidiasis. Multivariate analysis showed that ixekizumab [hazard ratio (HR) 3.45, P = 0.05] and atopic history (HR 5.43, P = 0.023) were significantly correlated with eczema, while bimekizumab (HR 23.30, P = 0.002) was significantly associated with candidiasis.

Conclusions

Anti-IL-17 treatments show varying risks of causing side effects such as eczema and candidiasis. Personalized strategies, regular monitoring and prophylactic measures are essential to improve patient outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PsoriasisInterleukin-17EczemaDermatologic AgentsDrug EruptionsCandidiasisHumansMaleFemaleRetrospective StudiesItalyMiddle AgedAntibodies, Monoclonal, HumanizedAdultRisk FactorsAged

Substanzen

Interleukin-17Antibodies, Monoclonal, HumanizedixekizumabsecukinumabDermatologic Agentsbrodalumabbimekizumab

Autor:innen und Institutionen

  • UOC di Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli - IRCCS, Rome,Italy.
  • Dermatologia, Dipartimento di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy.
  • Unit of Dermatology, Department of Internal Medicine and Medical Specialties, Sapienza University, Rome, Italy.
  • Department of Systems Medicine, University of Rome 'Tor Vergata', Rome, Italy.
  • Dermatology Unit, Azienda Ospedaliera Universitaria 'Policlinico Tor Vergata', Rome, Italy.
  • Dermatology Unit 'Daniele Innocenzi', Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Polo Pontino, Italy.

ORCID-Profile: Giacomo Caldarola, Simone Amato, Nicoletta Bernardini, Marco Galluzzo

Zitieren

APA

Caldarola, G., De Luca, E., Amato, S., Belcastro, A., Bernardini, N., Bianchi, L., Dattola, A., De Simone, C., Moretta, G., Pallotta, S., Peris, K., Richetta, A., Rossi, R., Skroza, N., & Galluzzo, M. (2025). Predictive factors for eczematous eruptions and candidiasis during anti-interleukin-17 treatment in patients with psoriasis: a multicentre real-life experience in Lazio region, Italy. Clinical and Experimental Dermatology. https://doi.org/10.1093/ced/llaf271

Vancouver

Caldarola G, De Luca E, Amato S, Belcastro A, Bernardini N, Bianchi L, et al. Predictive factors for eczematous eruptions and candidiasis during anti-interleukin-17 treatment in patients with psoriasis: a multicentre real-life experience in Lazio region, Italy. Clinical and Experimental Dermatology. 2025. doi:10.1093/ced/llaf271

BibTeX
@article{Caldarola2025,
  author = {Caldarola, Giacomo and De Luca, Eleonora and Amato, Simone and Belcastro, Alfredo and Bernardini, Nicoletta and Bianchi, Luca and Dattola, Annunziata and De Simone, Clara and Moretta, Gaia and Pallotta, Sabatino and Peris, Ketty and Richetta, Antonio and Rossi, Raimondo and Skroza, Nevena and Galluzzo, Marco},
  title = {Predictive factors for eczematous eruptions and candidiasis during anti-interleukin-17 treatment in patients with psoriasis: a multicentre real-life experience in Lazio region, Italy},
  journal = {Clinical and Experimental Dermatology},
  year = {2025},
  doi = {10.1093/ced/llaf271}
}
Kostenlos starten →